Cellectar Biosciences Inc (CLRB)

[protrade101]

From PR:
We will conduct a thorough analysis of all the data, and expect to present detailed Phase 3 lung cancer trial results later this year. Meanwhile, we are scheduled to present new NOV-002 preclinical data at the AACR Annual Meeting in April 2010, and we are on track for results from a NOV-002 Phase 2 breast cancer trial in 3Q 2010. We are also on track to initiate a Phase 2 hepatitis C trial shortly, with our second compound NOV-205."

From reading this, there is alot in the pipeline. I assume "shortly" means very soon. Also, there should be news again about the April Meeting. I'm sure the company is ready to get this going in the right direction.